BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 26070445)

  • 1. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
    Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
    Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.
    Hashimoto Y; Shimizu T; Mima Y; Abu Lila AS; Ishida T; Kiwada H
    Toxicol Appl Pharmacol; 2014 May; 277(1):30-8. PubMed ID: 24632081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
    Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
    Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
    Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
    Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
    Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
    Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time Interval of Two Injections and First-Dose Dependent of Accelerated Blood Clearance Phenomenon Induced by PEGylated Liposomal Gambogenic Acid: The Contribution of PEG-Specific IgM.
    Wang F; Ye X; Wu Y; Wang H; Sheng C; Peng D; Chen W
    J Pharm Sci; 2019 Jan; 108(1):641-651. PubMed ID: 30595169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of PEGylated liposome-associated proteins relating to the accelerated blood clearance phenomenon by combination with shotgun analysis and conventional methods.
    Kawanishi M; Hashimoto Y; Shimizu T; Sagawa I; Ishida T; Kiwada H
    Biotechnol Appl Biochem; 2015; 62(4):547-55. PubMed ID: 25196743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
    Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
    J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
    Wang X; Ishida T; Kiwada H
    J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice.
    Emam SE; Elsadek NE; Abu Lila AS; Takata H; Kawaguchi Y; Shimizu T; Ando H; Ishima Y; Ishida T
    J Control Release; 2021 Jun; 334():327-334. PubMed ID: 33957196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex-vivo/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by PEGylated liposome.
    Abu Lila AS; Ichihara M; Shimizu T; Ishida T; Kiwada H
    Biol Pharm Bull; 2013; 36(11):1842-8. PubMed ID: 24189428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response.
    Shimizu T; Ichihara M; Yoshioka Y; Ishida T; Nakagawa S; Kiwada H
    Biol Pharm Bull; 2012; 35(8):1336-42. PubMed ID: 22863934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon.
    Shiraishi K; Hamano M; Ma H; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Yokoyama M
    J Control Release; 2013 Feb; 165(3):183-90. PubMed ID: 23220106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM via a T Cell-Dependent Mechanism.
    Elsadek NE; Emam SE; Abu Lila AS; Shimizu T; Ando H; Ishima Y; Ishida T
    Biol Pharm Bull; 2020; 43(9):1393-1397. PubMed ID: 32879214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon.
    Shimizu T; Ishida T; Kiwada H
    Immunobiology; 2013 May; 218(5):725-32. PubMed ID: 22995937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.
    Kaminskas LM; McLeod VM; Porter CJ; Boyd BJ
    J Pharm Sci; 2011 Nov; 100(11):5069-77. PubMed ID: 21721002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery.
    Abu Lila AS; Uehara Y; Ishida T; Kiwada H
    J Pharm Sci; 2014 Feb; 103(2):557-66. PubMed ID: 24347396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice.
    Elsadek NE; Lila ASA; Emam SE; Shimizu T; Takata H; Ando H; Ishima Y; Ishida T
    Eur J Pharm Biopharm; 2020 Jul; 152():56-62. PubMed ID: 32376372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice.
    Elsadek NE; Hondo E; Shimizu T; Takata H; Abu Lila AS; Emam SE; Ando H; Ishima Y; Ishida T
    Mol Pharm; 2020 Aug; 17(8):2964-2970. PubMed ID: 32519877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery.
    Ichihara M; Moriyoshi N; Lila AS; Ishida T; Kiwada H
    Methods Mol Biol; 2013; 948():35-47. PubMed ID: 23070762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.